Beware toxicity in RA treat-to-target

Drug withdrawal due to toxicity is common in treat-to-target therapy for rheumatoid arthritis and significantly worsens patient-reported outcomes, Australian researchers report.

Data from 150 newly diagnosed RA patients showed over a third ceased at least one drug permanently after initiating a treat-to-target protocol.

Nearly 60% needed dose reduction or cessation of at least one drug over the three-year